- Conditions
- Pain
- Interventions
- Suzetrigine
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 14
- States / cities
- Anaheim, California • Bakersfield, California • Miami, Florida + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–45
of 21
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pain
- Interventions
- Suzetrigine, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Bellaire, Texas • Houston, Texas
- Conditions
- Thumb Basal Joint Osteoarthritis, Postoperative Pain, Joint Replacement Surgery, Joint Replacement
- Interventions
- suzetrigine 100mg, Acetaminophen
- Drug
- Lead sponsor
- Rothman Institute Orthopaedics
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pain
- Interventions
- SUZ
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 25 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Woburn, Massachusetts
- Conditions
- Pain
- Interventions
- Suzetrigine, Efavirenz
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- Suzetrigine
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 65
- States / cities
- Anniston, Alabama • Daphne, Alabama • Scottsdale, Arizona + 60 more
- Conditions
- Pain
- Interventions
- VX-548
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Opioid Consumption, Postoperative
- Interventions
- Suzetrigine, Standard Care (in control arm)
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Pain Control
- Interventions
- Suzetrigine (SUZ), Norco
- Drug
- Lead sponsor
- Jacob Lensing
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Acute Pain
- Interventions
- VX-548, HB/APAP, Placebo (matched to VX-548), Placebo (matched to HB/APAP)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 4 more
- Conditions
- Bariatric Surgery, Cardiac Surgery With Sternotomy, Post-operative Pain
- Interventions
- Suzetrigine, Placebo
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Postoperative Pain, Acute Pain, Skin Cancer, Cutaneous Malignancy, Mohs Surgery
- Interventions
- Suzetrigine, Acetaminophen Plus Ibuprofen
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 3
- States / cities
- Maple Grove, Minnesota • Minneapolis, Minnesota • Wyoming, Minnesota
- Conditions
- Pain
- Interventions
- VX-548, Moxifloxacin, Moxifloxacin Placebo, VX-548 Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Salt Lake City, Utah
- Conditions
- Acute Pain
- Interventions
- SUZ, HB/APAP, Placebo (matched to SUZ), Placebo (matched to HB/APAP)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,075 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 21
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 18 more
- Conditions
- Post Operative Pain
- Interventions
- Suzetrigine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Cutaneous Tumors, Mohs Micrographic Surgery
- Interventions
- Norco 5Mg-325Mg Tablet, Suzetrigine
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Analgesic Efficacy
- Interventions
- Suzetrigine, acetaminophen
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Pain, Acute Postoperative, Breast Disease
- Interventions
- suzetrigine
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Pain
- Interventions
- VX-548, Midazolam, Digoxin
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Acute Pain
- Interventions
- VX-548, HB/APAP, Placebo (matched to VX-548), Placebo (matched to HB/APAP)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 12
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 9 more
- Conditions
- Total Hip Arthroplasty (THA), Total Hip Arthroplasty \(THA\), Total Hip Replacement, Total Hip Replacement Surgery, Total Hip Replacements, Total Hip Replacement Arthroplasty, Suzetrigine, Pain Management, Pain, Nav 1.8, JOURNAVX, Opioid Cessation, Opioid Consumption, Postoperative, Multimodal Analgesia, Randomized Controlled Trial, Randomized Controlled Study, Randomized Controlled Trials
- Interventions
- Suzetrigine, Placebo
- Drug · Other
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York